Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family (DNA cotransfection-nude November 29, 1995) ABSTRACT The selective production of monoclonal antibodies (mAbs) reacting with defined cell surface-expressed molecules is now readily accomplished with an immunological subtraction approach, surface-epitope masking (SEM). Using SEM, prostate carcinoma (Pro 1.5) mAbs have been developed that react with tumor-associated antigens expressed on human prostate cancer cell lines and patient-derived carcinomas. Screening a human LNCaP prostate cancer cDNA expression library with the Pro 1.5 mAb identifies a gene, prostate carcinoma tumor antigen-1 (PCTA-1). PCTA-1 encodes a secreted protein of -35 kDa that shares "40% sequence homology with the N-amino terminal region of members of the S-type galactose-binding lectin (galectin) gene family. Specific galectins are found on the surface of human and murine neoplastic cells and have been implicated in tumorigenesis and metastasis. Primer pairs within the 3' untranslated region of PCTA-1 and reverse transcription-PCR demonstrate selective expression of PCTA-1 by prostate carcinomas versus normal prostate and benign prostatic hypertrophy. These findings document the use of the SEM procedure for generating mAbs reacting with tumorassociated antigens expressed on human prostate cancers. The SEM-derived mAbs have been used for expression cloning the gene encoding this human tumor antigen. The approaches described in this paper, SEM combined with expression cloning, should prove of wide utility for developing immunological reagents specific for and identifying genes relevant to human cancer.
The early detection of prostate cancer and the accurate prediction of its clinical course is not possible by using current methodologies. Contemporary approaches, including physical examination, tissue biopsy, monitoring serum prostate-specific antigen (PSA) levels, and ultrasound and bone scans do not ensure early prostate cancer detection and are of only limited value in predicting disease progression. Of immense value for the accurate diagnosis and potentially for the therapy of human prostate cancer is the identification of immunological and genetic reagents displaying the appropriate specificity that will permit a clear distinction between prostate carcinoma versus normal prostate and benign prostatic hypertrophy (BPH). Immunological reagents that can detect and bind to tumor-associated antigens on the surface of prostate carcinoma cells, and that display limited expression on normal prostate and BPH tissue, may prove of particular benefit for the detection and ultimately for the therapy of prostate cancer.
Production of monoclonal antibodies (mAbs) reacting with antigens present on the surface of tumor cells, but displaying restricted expression on normal cells, is often a difficult and inefficient process (1) (2) (3) . A procedure based on immunological subtraction, surface-epitope masking (SEM), has been developed that in principle can obviate many of the limitations preventing efficient mAb development toward molecules expressed on the cell surface (3, 4) . SEM is based on the selective blocking of antigens on a genetically modified target cell (i.e., tester) with polyclonal antibodies produced against the same unmodified cell line (i.e., driver). Antigen-blocked cells are injected into BALB/c mice, and sensitized spleen cells are removed and fused to NS1 myeloma cells, and hybridomas secreting reactive mAbs are isolated (3) . The SEM approach has been successfully used for a number of applications, resulting in the production of mAbs specific for surface expressed molecules with known and unknown functions (3, 4) .
An improved procedure has been developed for identifying and cloning dominant acting oncogenes, termed rapid expression cloning (5, 6) . This approach involves transfecting high molecular weight human tumor DNA into a new acceptor cell line, CREF-Trans 6, selecting cells expressing genes inducing tumors in nude mice, and using molecular biological approaches, such as differential RNA display, to clone the putative oncogene (5, 6) . Tumor-derived CREF-Trans 6 cells have also proven useful in combination with the SEM procedure for identifying tumor-associated antigens expressed on the cell surface of cancer cells serving as the initial source for transforming DNA (5, 6) . Expression cloning of cDNAs using antibodies reacting with their encoded proteins represents a direct means of identifying and cloning functional genes (2) . This approach has now been used to identify and clone a gene, prostate carcinoma tumor antigen 1 (PC1TA-1), encoding tumor-associated antigens (TAAs) recognized by the prostate carcinoma mAb Pro 1.5. Sequence analysis indicates that PCTA-1 consists of a cDNA of 3.85 kb with 83% nucleotide (nt) and 81% amino acid (aa) sequence homology to an -1.25-kb cDNA, rat galectin-8, cloned from a rat liver cDNA expression library (7) . Some overlapping homologies are also detected with several small noncontiguous partial cDNA sequences (of less than 500 nt) previously identified as expressed human sequence tags (8) . Analysis of protein structure indicates that PCTA-1 has -40% homology to specific structural domains of the S-type lectin family of galactose-binding proteins, the galectins (9) (10) (11) (9) (10) (11) . The roles of the galectin proteins are diverse and impinge upon important biological processes, including cell signaling, proliferative control, cell adhesion, and cell migration (9) (10) (11) . In this context, the demonstration that PCTA-1 encodes a protein with specific homologies to the galectins suggests that this molecule, a human tumor homologue of rat galectin-8 (i.e., galectin-8HT), may contribute to human prostate cancer development and evolution.
MATERIALS AND METHODS
Cell Lines. The LNCaP cell line was derived from metastatic deposits from a patient with advanced prostate cancer (12) .
CREF-Trans 6 and LNCaP DNA-transfected nude mouse tumor-derived CREF-Trans 6 cells, CREF-Trans 6:4 NMT, were isolated as described (5) . The hormone independent prostatic carcinoma cell lines DU-145 and PC-3 were obtained from the American Type Culture Collection. Conditions for growing the various cell types were as described (5, 6, 12) .
cDNA Library Construction, Expression Cloning, and Sequencing. An LNCaP cDNA library was constructed in the Uni-ZAP XR vector (Stratagene) (6, 13, 14) . The performed by using a rabbit reticulocyte lysate translation kit with conditions as described by GIBCO/BRL (6) .
Preparation of Mouse Polyclonal Antibodies and SEM. CREF-Trans 6 polyclonal antibodies were prepared as described (3). The CREF-Trans 6 polyclonal antibodies were used to coat CREF-Trans 6:4 NMT cells by the SEM approach, resulting in the production of hybridomas secreting Pro 1.5 mAbs (3).
Fluorescence Cell Staining and Immunostaining of Tissue Sections with Pro 1.5 and PSA. Fluorescence staining with Pro 1.5 mAb was as described (16) . Tissue sections were prepared from fresh tissues frozen in liquid nitrogen. Serial sections for several tissues were used to prepare RNA for reverse transcription (RT)-PCR (6) . Tissue sections were stained by using standard protocols [Super Sensitive Detection System (BioGenex Laboratories, San Ramon, CA)]. Briefly, sections were fixed in acetone, blocked with 3% H202 for 7 min at room temperature, and incubated for 20 min at room temperature in phosphate-buffered saline (PBS) containing 3% lamb serum. Sections were then incubated with Pro 1.5 (1:100) or PSA (1:200) (Dako) for 45 min at room temperature. Samples were incubated with biotinylated secondary antibody and horseradish peroxidase conjugated streptavidin in PBS. Prior to each incubation step, sections were washed three to five with PBS. Reactivity was detected by adding diaminobenzidine and counterstaining with Hematoxylin.
Immunoprecipitation Analysis. Cells were labeled with
[35S]methionine and cell lysates were analyzed for PCTA-1
protein levels by immunoprecipitation analysis using Pro 1.5 mAbs as described (3, 17) . Secreted PCTA-1 was detected by labeling cells for 4 
hr with [35S]methionine, growing cells for
an additional 24 hr in the absence of label, collecting the medium, concentrating the medium, and performing immunoprecipitation analysis with Pro 1.5 mAbs. RNA Preparation and RT-PCR. Total cytoplasmic RNA was isolated from logarithmically growing cell cultures as described (6, 14) . Tissue samples from normal prostates and patients with prostatic carcinomas or BPH were frozen in liquid nitrogen, and RNA was isolated using the TRIzol reagent as described by GIBCO/BRL. Tissue samples were supplied by the Cooperative Human Tumor Network. Three samples of normal prostate were obtained from autopsies of males <40 years of age. All tissues were histologically confirmed as normal, BPH, or carcinoma of the prostate (6). RT-PCR using primer pairs for PCTA-1, PSA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was performed as described (6, 17) . and secondary tumor-derived CREF-Trans 6, LNCaP, DU-145, and PC-3 cells (3) (Fig. 1D and data not shown) . Of the prostate cancer cell lines studied, the PC-3 clone contains the lowest quantities of cell-associated, surface-expressed (FACS) and secreted PCTA-1 protein.
To determine if Pro 1.5 mAbs can react with patient-derived prostate cancer specimens, frozen sections were prepared from normal (males <40 years of age), BPH, and carcinomas of the prostate. Normal prostate displays limited reactivity with Pro 1.5, whereas PSA readily stains normal prostate (A) . (12, 13) . This approach resulted in the identification of a 3.85-kb cDNA clone referred to as PCTA-1. In vitro protein translation of the PCTA-I cDNA results in a 317-aa protein of -35 kDa (data not shown). The DNA sequence of PCTA-1 displays 83% homology, and the protein sequence of PCTA-1 displays 81% sequence homology with rat galectin-8 (7), a member of the S-lectin family of galactose-binding lectin proteins. The fulllength rat galectin-8 cDNA is 1247 bp, whereas the full-length PCTA-1 cDNA is 3850 bp. This result suggests that PCTA-1 encodes a human tumor homologue of galectin-8, galectin-8HT. Amino acid comparison of PCTA-1 with other members of the galectin gene family indicates that this protein is -40% homologous to specific regions of these galectins (Fig. 3) . Several amino acid sequence homologies are found between PCTA-1, rat galectin-8, and the other galectins. Stretches of identical amino acids are found in PCTA-1, rat galectin-8, and both the small '14-kDa and larger -29-to 34-kDa galectins, e.g., HFNPRF, IVCN, and WG. These amino acids are well conserved and are found in galectins isolated from diverse species, including eel, chicken, mouse, rat, bovine, and human ( Fig. 3B) (11, 19, 20) . They are important structural components of the galectins and may mediate galectin binding to its putative ligands (12) . Of potential interest is the replacement in PCTA-1 of two amino acids normally present in the conserved regions of most of the galectins-i.e., the substitu- 
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Rat-Galectin-8 Human-L3 1 Rat-Galectin-8 PCTA-1 Mr 14 ,000 and Mr 29,000-35,000 galectins from eel, chicken, mouse, rat, bovine, and human galectins. *, Amino acids unique to PCTA-1 and rat galectin-8; *A,, amino acid differences between PCTA-1 and rat galectin-8; A, amino acids shared by PCTA-1, rat galectin-8, mouse-L34, human galectin-3-L29, and human-L31; AE, amino acid difference between PCTA-1, human galectin-3-L29, and human-L31 versus rat galectin-8; 0, amino acids shared by PCTA-1, rat galectin-8, and the Mr 14,000 and Mr 29,000-31,000 galectins from different species. tion of an I for an R and a T for an F (Fig. 3B) . The I for an R substitution is also found in rat galectin-8, whereas an M for F substitution is found in rat galectin-8. A number of similar positioned amino acids are found in PCTA-1, rat galectin-8, and the larger -29-to 34-kDa galectins that are not present in the 14-kDa galectins isolated from most other species-e.g., DVAF (Fig. 3B) . The amino acid sequence WGREE is conserved in PCTA-1 and the human -29-to 34-kDa human galectins but is not present in the L34 mouse galectin (WG-KEE) or rat galectin-8 (WGWEE). In addition, a number of amino acids are distinct for PCTA-1 and rat galectin-8 versus the other similarly positioned amino acids that are found in the human galectin-3 L29 and human L-31 proteins, including RA, RFKR, CIVC, and EEIT. A number of amino acid changes also distinguish PCTA-1 from rat galectin-8, including KRAG, LINE, and TYDTPFKRE. The similarities in regions of conserved structure between PCTA-1, rat galectin-8, and the other galectins suggest that they will share a number of overlapping properties. However, the numerous amino acid changes observed in PCTA-1, in both the conserved regions and throughout the remainder of this protein, can be expected to impact on the structure and affect the properties of the PCTA-1 protein.
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Expression of PCTA-1 in Cell Lines and Normal Prostate, BPH, and Prostate Carcinomas. After obtaining the sequence of PCTA-1, studies were performed to determine if primers for specific regions of this gene could be identified that would permit detection of RNA expression by RT-PCR. Using primers located between bp 3010 and 3423 in the 3' untranslated region, PCTA-1 expression is apparent in LNCaP DNAtransfected tumor-derived CREF-Trans 6, LNCaP, and DU-145 cells but not in untransfected CREF-Trans 6 cells (Fig. 4) . PCTA-1 expression also occurs in seven of seven patientderived prostate carcinomas, one of four BPH, and one of four putative normal prostate tissue samples (Fig. 4) . In the one BPH sample displaying PCTA-1 expression, histological anal- ysis indicates the presence of epithelial atypia consistent with PIN. In the one putative normal prostate tissue sample expressing PCTA-1, no tissue was available for histological analysis. However, because this tissue was obtained from a 60-year-old male, it is possible that this tissue may have contained clinically unsuspected prostate disease. The same RNA samples were tested for PSA expression (Fig. 4) . PSA was detected by RT-PCR in LNCaP cells and all of the prostate tissue samples, but not in CREF-Trans 6, LNCaP DNAtransfected tumor-derived CREF-Trans 6, or DU-145 cells. As predicted, all samples were positive for expression of the housekeeping gene GAPDH (Fig. 4) . Although the sampling size is small, these results indicate that PCTA-1 expression may be restricted to prostate carcinomas and subsets of BPH displaying early stages of cancer (i.e., PIN). In contrast, PCTA-1 expression is not evident in normal prostate or BPH. Secretion of PCTA-1 by Human Prostate Carcinoma Cell Lines. Many galectins are externalized by nonclassical secretory mechanisms that do not involve a typical secretion signal peptide (11, 18, 21) . To determine if PCTA-1 is secreted by Pro 1.5 mAb positive cells, target cells were labeled for 4 hr with [35S]methionine, the label was removed, and cells were washed three times in methionine-free medium and then incubated for an additional 18-24 hr in complete medium without label. The conditioned medium (CM) was collected, contaminating cells were removed, and the CM was concentrated and immunoprecipitated using the Pro 1.5 mAb (Fig. 1C) . Under these experimental conditions, no reduction in cell viability was evident. A protein of -35-42 kDa was present in CM from CREF-Trans 6:4 NMT, LNCaP, DU-145, and PC-3, but not from CM obtained from CREF-Trans 6 cells (Fig. 1C) Prior to SEM, no simple and direct procedure was available for efficiently generating mAbs reacting with differentially expressed surface molecules. Conceptually, SEM involves immunological subtraction that induces the immune system of mice to target antibody production toward surface molecules expressed on a genetically modified tester cell line, but not expressed or expressed in lower abundance on its' cognate unmodified driver cell line (3, 4) . By using polyclonal antibodies produced against the driver cell line to coat (mask) epitopes on the tester cell line, enriched production of mAbs targeted toward epitopes expressed on the surface of the tester cell type is achieved (3, 4) . Confirmation of the SEM approach has come from studies in which this process was used to target the development of mAbs reacting with the Mr 170,000 human multidrug resistance protein (P-glycoprotein) and the human interferon y receptor (3, 4) . The SEM approach has also been used to produce mAbs that react with unknown TAAs, including those presently identified as the gene product of PCTA-1 and undefined TAAs transferred by rapid expression cloning from the T47D human breast carcinoma cell line to CREF-Trans 6 (data not shown). These results indicate that rapid expression cloning combined with SEM may represent efficient strategies for identifying antigenic epitopes on human cancers. Additional applications of SEM may also result in the targeted production of mAbs and the identification of genes associated with important physiological processes, including cellular growth and differentiation, immunological recognition, tumorigenesis, metastasis, cellular senescence, atypical multiple drug resistance, and autoimmune disease.
In summary, we presently demonstrate direct applications of the rapid expression cloning and SEM technologies for the development of mAbs and the cloning of the PCTA-1 gene associated with human prostate cancer. The PCTA-1 gene and the recently identified prostate tumor inducing gene PTI-1 (6) are genetic elements that can distinguish prostate cancer from normal prostate and BPH. Although further studies are required, it appears that PCTA-1 may represent an earlier genetic change in human prostate cancer development than PTI-1. In this context, both the Pro mAbs and the PCTA-1 gene should find direct applications for prostate cancer diagnosis and staging, and they may also represent important therapeutic reagents for intervention in this pervasive and often fatal neoplastic disease.
